Trial design and participants
amnestic syndrome, Alzheimer’s clinical syndrome
The trial included participants age ≥ 50 years with Alzheimer’s clinical syndrome (—recommended terminology for clinically ascertained multi- (or single-) domain amnestic syndrome or a classic syndromal variant (what has historically been labeled “possible or probable AD”)) [Eligible participants had a Global Deterioration Scale (GDS) score of 3 to 5 (inclusive). Procedures also included magnetic resonance imaging (MRI) consistent with AD [In addition, cell DNA was extracted and apolipoprotein E (APOE) genotype determined by PCR, following the standard protocol for determination of the APOE ε4 carrier or non-carrier.